Equities

Mirion Technologies Inc

Mirion Technologies Inc

Actions
  • Price (EUR)14.40
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+89.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets. The Company's segments include Medical and Technologies. The Medical segment includes products and services for radiation therapy and personal dosimetry. This segment's offerings include solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy; solutions for monitoring the total amount of radiation medical staff members are exposed to over time, and products for nuclear medicine in radiation measurement, shielding, product handling, medical imaging furniture and rehabilitation. The Technologies segment includes products and services for defense, nuclear energy, laboratories and research and other industrial markets. This segment's offerings include reactor safety and control systems, and radiological search, measurement and analysis systems.

  • Revenue in USD (TTM)836.90m
  • Net income in USD-66.30m
  • Incorporated2018
  • Employees3.00k
  • Location
    Mirion Technologies Inc1218 Menlo DriveATLANTA 30318United StatesUSA
  • Phone+1 (770) 432-2744
  • Fax+1 (302) 636-5454
  • Websitehttps://www.mirion.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.